Period | Date | Adjusted Actuals EPS | GAAP EPS |
---|---|---|---|
Q3 2022 | 2022-11-01 | Future report Set alerts | |
Q2 2022 | 2022-08-03 | 0.05 | 0.05 |
Q1 2022 | 2022-05-05 | -0.11 | -0.11 |
Q4 2021 | 2022-02-23 | 0.00 | 0.00 |
Q3 2021 | 2021-11-03 | 0.14 | 0.14 |
Q2 2021 | 2021-07-28 | 0.17 | 0.17 |
Q1 2021 | 2021-05-05 | 0.15 | 0.15 |
Q4 2020 | 2021-02-10 | 0.15 | 0.15 |
Q3 2020 | 2020-10-28 | 0.11 | 0.11 |
Q2 2020 | 2020-08-05 | 0.16 | 0.16 |
2016-06-10 | Reiterated Rating | Jefferies Group | Buy | |
2016-06-06 | Reiterated Rating | Brean Capital | Buy | |
2016-05-29 | Reiterated Rating | Jefferies Group | Buy | |
2016-05-27 | Reiterated Rating | Brean Capital | Buy | $20.00 |
2016-05-07 | Reiterated Rating | Jefferies Group | Buy | $15.00 |
2016-04-27 | Reiterated Rating | Brean Capital | Buy | $20.00 |
2016-03-14 | Reiterated Rating | Canaccord Genuity | Buy | $18.00 |
2016-03-09 | Lower Price Target | JMP Securities | Market Outperform | $30.00 to $18.00 |
2016-02-12 | Reiterated Rating | Canaccord Genuity | Buy | $18.00 |
2016-02-10 | Reiterated Rating | Piper Jaffray | Buy | |
2016-02-10 | Reiterated Rating | Piper Jaffray Cos. | Buy | |
2016-02-07 | Reiterated Rating | Brean Capital | Buy | $20.00 |
2016-01-06 | Reiterated Rating | Piper Jaffray | Overweight | $16.00 |
2015-12-18 | Reiterated Rating | Brean Capital | Buy | $20.00 |
2015-12-03 | Reiterated Rating | Piper Jaffray | Overweight | $16.00 |
2015-11-04 | Reiterated Rating | Brean Capital | Buy | $20.00 |
2015-11-04 | Lower Price Target | Jefferies Group | Buy | $20.00 to $15.00 |
2015-10-21 | Initiated Coverage | Brean Capital | Buy | $20.00 |
2015-09-24 | Reiterated Rating | Canaccord Genuity | Buy | $18.00 |
2015-09-02 | Reiterated Rating | Piper Jaffray | Buy | $16.00 |
2015-07-30 | Reiterated Rating | Canaccord Genuity | Buy | $18.00 |
2015-07-30 | Reiterated Rating | Piper Jaffray | Overweight | $16.00 |
2015-06-03 | Reiterated Rating | Canaccord Genuity | Buy | $18.00 |
2015-05-07 | Reiterated Rating | Canaccord Genuity | Buy | $22.00 to $18.00 |
2015-05-06 | Set Price Target | Piper Jaffray | Buy | $15.00 |
2015-03-09 | Initiated Coverage | Jefferies Group | Buy | $20.00 |
2015-03-09 | Reiterated Rating | Piper Jaffray | Overweight | $18.00 |
2015-02-22 | Reiterated Rating | Piper Jaffray | Overweight | $18.00 |
2015-02-20 | Lower Price Target | Jefferies Group | Market Outperform | $33.00 to $30.00 |
2015-01-09 | Initiated Coverage | Canaccord Genuity | Buy | $22.00 |
2014-12-24 | Set Price Target | Piper Jaffray | Buy | $25.00 |
2013-11-26 | Initiated Coverage | Piper Jaffray | Overweight | $21.00 |
2013-11-15 | Boost Price Target | Jefferies Group | Buy | $13.00 to $20.00 |
2013-11-15 | Set Price Target | JMP Securities | Market Outperform | $19.00 to $23.00 |
2013-10-21 | Reiterated Rating | Lazard Capital Markets | Buy | $22.00 |
2010-03-10 | Initiated | Hapoalim | Outperform | $23 |
2009-12-09 | Initiated | Jefferies & Co | Buy | $22 |
2008-07-29 | Downgrade | Banc of America Sec | Buy to Neutral | |
2008-07-28 | Downgrade | Caris & Company | Buy to Above Average | $22 to $3 |
2008-05-02 | Initiated | Caris & Company | Buy | $22 |
2007-09-10 | Initiated | Banc of America Sec | Buy | |
2007-05-08 | Initiated | Citigroup | Hold | |
2007-05-01 | Reiterated | Friedman Billings | Outperform | $40 to $37 |
2007-02-14 | Initiated | Friedman Billings | Outperform | $40 |
2016-06-10 | Reiterated Rating | Jefferies Group | Buy | |
2016-06-06 | Reiterated Rating | Brean Capital | Buy | |
2016-05-29 | Reiterated Rating | Jefferies Group | Buy | |
2016-05-27 | Reiterated Rating | Brean Capital | Buy | $20.00 |
2016-05-07 | Reiterated Rating | Jefferies Group | Buy | $15.00 |
There is presents forecasts of rating agencies and recommendations for investors about this ticker
In VNDA 153 funds of 2213 total. Show all
Fund name | Ticker shares |
---|---|
BlackRock Inc. | 9.80M |
Vanguard Group, Inc | 3.89M |
STATE STREET CORP | 3.69M |
RENAISSANCE TECHNOLOGIES LLC | 3.30M |
MACQUARIE GROUP LTD | 2.93M |
DIMENSIONAL FUND ADVISORS LP | 2.73M |
Epoch Investment Partners, Inc. | 2.72M |
BlackRock Fund Advisors | 2.27M |
Palo Alto Investors, LLC | 2.17M |
GOLDMAN SACHS GROUP INC | 1.83M |
BlackRock Institutional Trust Company, N.A. | 1.22M |
Nuveen Asset Management, LLC | 1.08M |
GEODE CAPITAL MANAGEMENT, LLC | 1.03M |
HOTCHKIS & WILEY CAPITAL MANAGEMENT LLC | 0.94M |
AMERIPRISE FINANCIAL INC | 0.91M |
Name Relationship | Total Shares | Holding stocks |
---|---|---|
TANG KEVIN C | 8.02% (2715852) | ARDM / CYCC / HRTX / LJPC / ODT / VNDA / |
Polymeropoulos Mihael Hristos Chief Executive Officer | 3.49% (1182872) | VNDA / |
Flynn James E Possible Member of 10% Group | 3.26% (1103617) | AAVL / ALIM / ASPX / ATRS / AUXL / AXGN / CASM / CYCC / DRNA / EHTH / EMAG / FIXX / HITK / LOXO / NURO / PRTO / REPH / RIGL / STRM / TRGT / TWTI / VNDA / XNPT / |
Kelly James Patrick SVP, CFO, Sec & Treasurer | 0.59% (199534) | VNDA / |
Clark William D Sr. VP, Chief Business Officer | 0.50% (168279) | GNCA / VNDA / |
Reverberi Gian Piero SVP, General Manager Europe | 0.41% (140000) | VNDA / |
Birznieks Gunther SVP, Business Development | 0.41% (139841) | VNDA / |
Gulino Richard L. SVP & General Counsel | 0.34% (115073) | VNDA / |
Baroldi Paolo SVP & Chief Medical Officer | 0.16% (54365) | VNDA / |
DUGAN RICHARD W | 0.08% (25770) | VNDA / |
Watkins Thomas | 0.06% (20000) | HZNP / VNDA / |
Repella Robert SVP & Chief Commercial Officer | 0.04% (15000) | VNDA / |
Feeney John Joseph Acting Chief Medical Officer | 0.04% (11942) | VNDA / |
Halak Brian K | 0.02% (7276) | ACHN / AKAO / ALIM / CADX / CLVS / DRNA / DRTX / ESPR / EVOK / OCRX / OREX / TNDM / VCYT / VNDA / ZGNX / |
COLA MICHAEL F | 0.01% (5000) | MDGN / PATH / SAGE / VNDA / |
MILANO VINCENT | 0.01% (5000) | IDRA / VNDA / VPHM / |
BATE KENNETH | 0.01% (5000) | AVEO / BMRN / CBST / EPZM / GNCA / SNTA / VNDA / |
Irish Stephanie Rast Acting CFO/Treasurer | 0.01% (2249) | VNDA / |